罗沙司他与重组人促红素治疗慢性肾衰竭并肾性贫血的临床疗效与安全性研究  

Clinical Efficacy and Safety Study of Roxostat and Recombinant Human Hormone in Chronic Renal Failure and Renal Anemia

作　　者：夏树芹 朱时法 闫慧 XIA Shuqin;ZHU Shifa;YAN Hui(Department of Nephrology,Lianyungang Ganyu District People’s Hospital,Lianyungang,Jiangsu 222199,China)

机构地区：[1]连云港市赣榆区人民医院肾内科,江苏连云港222199

出　　处：《中国医药指南》2025年第7期49-51,共3页Guide of China Medicine

摘　　要：目的分析罗沙司他与重组人促红素治疗慢性肾衰竭并肾性贫血的价值。方法选取连云港市赣榆区人民医院2022年1月至2024年3月收治的139例慢性肾衰竭并肾性贫血患者,随机数字表法分两组,对照组69例以重组人促红素治疗,研究组70例在对照组基础上采用罗沙司他胶囊,对比两组临床疗效、肾功能指标(血肌酐、24 h尿蛋白、尿素氮、总蛋白、血清白蛋白)水平、炎症因子(C反应蛋白、白细胞介素8、白细胞介素6)水平、不良反应。结果研究组治疗有效率为98.57%,高于对照组的88.41%(P<0.05);治疗后,研究组血肌酐、24 h尿蛋白定量、尿素氮水平低于对照组,总蛋白、血清白蛋白高于对照组(均P<0.05);治疗后,研究组各项炎症因子水平均低于对照组(均P<0.05);两组不良反应发生率对比,P>0.05。结论罗沙司他与重组人促红素在治疗慢性肾衰竭并肾性贫血方面具有较高临床疗效,能够增强患者肾功能,降低炎症因子水平,不良反应风险较低。Objective To analyze the value of rodose and recombinant human pro-stimulating hormone in the treatment of chronic renal failure and renal anemia.Methods A total of 139 patients with chronic renal failure and renal anemia admitted to Ganyu District People’s Hospital of Lianyungang City from January 2022 to March 2024 were randomly divided into two groups,69 cases in the control group were treated with recombinant human erythropoietin and 70 cases in the study group were treated with roxadustat capsule on the basis of the control group,and the clinical efficacy of the two groups was compared,and the levels of renal function indexes(serum creatinine,24-hour urine protein,urea nitrogen,total protein,serum albumin)and inflammatory factors(C-reactive protein,interleukin 8,interleukin 6)levels were compared,adverse reactions.Results The effective rate of the study group was 98.57%,which was higher than that of the control group(88.41%)(P<0.05),and the serum creatinine,24-hour urine protein and urea nitrogen levels in the study group were lower than those in the control group,and the total protein and serum albumin were higher than those in the control group(all P<0.05),and the levels of various inflammatory factors in the study group were lower than those in the control group(all P<0.05),and the incidence of adverse reactions in the two groups was compared,P>0.05.Conclusions Roxostat and recombinant human tropin have high clinical efficacy in the treatment of chronic renal failure and renal anemia,enhancing renal function,reducing the level of inflammatory factors,and low risk of adverse reactions.

关 键 词：罗沙司他 重组人促红素 肾衰竭 肾性贫血 临床疗效 安全性 

分 类 号：R692.5[医药卫生—泌尿科学] R556[医药卫生—外科学]